On Thursday, Vigil Neuroscience Inc. (NASDAQ:VIGL) released data from its completed Phase 1 trial evaluating VG-3927 as a potential treatment for Alzheimer’s disease. Demonstrated a favorable ...
Vigil Neuroscience plans a Phase 2 trial for Alzheimer's in Q3 2025, advancing a once-daily 25mg oral dose. The company plans to advance a once-daily oral dose of 25mg and expects to initiate the ...
Commission will be hosting a Legacy With Candlelight Vigil, Fireworks Spectacular in ... to arrive early to get a good spot to view the show, and to bring chairs or blankets to be comfortable.
A Vernon group organized a show of solidarity with Palestinians as the war between Israel and Hamas rages on in the Middle East. Vernon 4 Palestine hosted the vigil at Vernon's Spirit Square Sunday, ...
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease. In a possible ...